Azithromycin showed a synergistic effect in combination with hydroxychloroquine in vitro against SARS‐CoV‐2 at realistic concentrations reachable in the human lung. Clinical trials with this antibiotic were initiated in New York on 24 March 2020. 243  Very recently, however, the clinical benefit of the drug in COVID‐19 patients was called into question. 82